source
- Roivant's inhaled drug mosliciguat achieves positive Phase 2 results in interstitial lung diseaseRoivant Sciences reported that its inhaled candidate mosliciguat has successfully completed a Phase 2 trial in patients with interstitial lung disease. The study met its primary endpoint, showing a…
- Roivant's mosliciguat shows strong Phase 2 results, advancing to Phase 3 for PH-ILDMosliciguat, the pulmonary hypertension candidate from Roivant Sciences subsidiary Pulmovant, cut pulmonary vascular resistance by more than 56% in a Phase 2 trial of patients with PH‑ILD, surpassi…